Krazati 200 mg Tablet
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Krazati 200 mg Tablet contains adagrasib, a KRAS G12C inhibitor. Its labelling describes it as a treatment for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy, with the mutation confirmed by a validated test.
Product Information
The following description reflects information associated with adagrasib and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
- Described for patients who have had at least one prior systemic therapy
- Use is described as guided by a validated test confirming the KRAS G12C mutation
Described Dosage & Administration
- Taken by mouth, with or without food, twice daily or exactly as prescribed
- Swallowed whole; the labelling describes not chewing, crushing or splitting the tablet
- Doses are described as taken about 12 hours apart and not doubled if one is missed
Described Side Effects
Commonly described side effects include:
- Nausea, vomiting and diarrhoea
- Fatigue
- Loss of appetite
- Abdominal pain
- Described as possibly affecting the liver, kidneys, heart rhythm (QT prolongation) and blood counts
Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Full medical history, including heart or liver conditions, should be shared with the doctor
- Blood tests, ECG and other monitoring are described in the labelling during treatment
- New breathlessness, cough, palpitations or jaundice should be reported promptly
- Pregnancy, planned pregnancy or breastfeeding should be discussed with the prescriber
- Other medicines and supplements should be disclosed to avoid interactions
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains adagrasib and is described for adults with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. SDO Pharma has not independently verified these claims.
Its labelling describes patient selection based on a validated test confirming a KRAS G12C mutation.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.